1-(+)-Dehydroabietyl原因imidazolium Salts as Enantiomer Discriminators for NMR Spectroscopy

Gunaratne, H. Q. N., Laaksonen, T., Seddon, K. R., & Wähälä, K. (2017). 1-(+)-Dehydroabietyl原因imidazolium Salts as Enantiomer Discriminators for NMR Spectroscopy. *Australian Journal of Chemistry*, 70(7).
<https://doi.org/10.1071/CH16545>

Published in:
Australian Journal of Chemistry

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights
© 2017 CSIRO.

This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

1-(-)-Dehydroabietylimidazolium Salts as Enantiomer Discriminators for NMR Spectroscopy

H. Q. Nimal Gunaratne,^B Tiina Laaksonen,^A Kenneth R. Seddon^B and Kristiina Wähälä^A

^A Department of Chemistry, University of Helsinki, A.I. Virtasen aukio 1, P.O. Box 55, FI-00014 University of Helsinki, Finland, E-mail: kristiina.wahala@helsinki.fi

^B QUILL Research Centre, School of Chemistry and Chemical Engineering, The Queen's University of Belfast, Belfast BT9 5AG, Northern Ireland, UK

Nine new (+)-dehydroabietylimidazolium salts were synthesised and studied as chiral solvating agents for a number of different racemic aromatic and nonaromatic carboxylate salts. These cationic chiral solvating agents resolve racemic ionic analytes better than non-ionic ones. Bis(dehydroabietylimidazolium) bis(trifluoromethanesulfonimide) gave the best discrimination for the enantiomers of carboxylate salts. Its resolution behaviour was studied by an NMR titration experiment, which indicated 1:1 complexation with the racemic analyte. The dehydroabietylimidazolium salts were also useful in enantiomeric excess (*ee*) determinations, and for the recognition of chirality of racemic aromatic and non-aromatic α -substituted carboxylic acids.

Introduction

The determination of enantiomeric purity is an important aspect of synthetic chemistry and various methods have been developed for this purpose. Compared to commonly used techniques (*e.g.*, HPLC), the determination of enantiomeric purity by NMR spectroscopy has been less frequently used as a tool in synthesis monitoring. Due to the development of higher field instruments, NMR spectroscopy has become more sensitive,¹ and the enantiomeric excess (*ee*) may be determined up to a 94-99% level.² This allows reliable, accurate and expedient *ee* determinations³ required particularly in pharmaceuticals development. Minimal sample preparation, ease of use and fast analyses make NMR spectroscopy an optimal tool for quick *ee* determinations.

The NMR spectra of enantiomers are indistinguishable as their chemical environments are identical. To differentiate the enantiomers, a diastereomeric environment is required. This can be created by using chiral auxiliary compounds such as chiral solvating agents, paramagnetic chiral shift reagents, chiral liquid crystals, or chiral derivatising agents.^{4,5} Chiral solvating agents are most often employed due to their ease of use. Both neutral and ionic chiral solvating agents have been developed, although the latter have gathered less attention.^{4,5}

The use of chiral solvating agents is based on the complexation between the chiral solvating agent (host) and the two enantiomers of the chiral substrate (guest), to generate two diastereomeric 'complexes'.^{4,5} Complexation between a host and guest depends on interactions such as hydrogen bonding, π - π stacking and ion-ion interactions.⁵ Aromatic moieties in chiral solvating agents can enable π - π stacking but, more importantly, they can also provide shielding which increases resolution.^{4,6} Therefore most of the chiral solvating agents developed are aromatic and they can be used for both aromatic and non-aromatic chiral compounds.⁷ Electronegative groups and hydrogen donor and/or acceptor groups are able to provide the needed interaction to create a host-guest complex.^{4,5} Bulky substituents are also useful, as they can obstruct complex formation for the other enantiomer, thus increasing the chemical shift difference.¹ In the case of an ionic chiral solvating agent, the counter ion will also have an effect on the degree of resolution. Counter ions with a delocalised charge are often favoured as they have been observed to increase resolution.⁸

Our aim was to develop and investigate new ionic chiral solvating agents, as they have not been widely studied. The resin derivative (+)-dehydroabietylamine is known to have an enantiomeric recognition ability towards chiral carboxylic acids⁹ but, apart from recent work from our group,^{10,11} (+)-dehydroabietylamine has not been used as a chiral solvating agent. As it is readily available, derived from renewable resources at a low cost, has a bulky structure, and contains both an aromatic moiety and an amine group that may also be converted to the cationic form, it should provide an ideal starting material for cationic chiral solvating agents. Although some cationic chiral solvating agents have been reported, their resolution ability has been scantily studied. In most cases, the developed chiral solvating agents have only been tested with one guest.¹² A lack of comparison with a number of compounds hinders the establishment of the full potential of a developed chiral solvating agent in enantiomeric resolutions. The resolution ability of newly developed cationic chiral solvating agents has been more extensively investigated in a few cases only,^{10,13} predominantly with racemic aromatic carboxylic acids.^{10,12-14} The favoured test compound has been Mosher's acid (3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid), used either as such¹⁴ or in its anionic¹² form.

Here, ten different (+)-dehydroabietylimidazolium or (+)-dehydroabietylimidazolinium chiral solvating agents were prepared (Scheme 1). Their effectiveness as chiral discriminators was extensively investigated, along with the effect of the anion on the resolution, the effect of the aromatic functionality, and the question as to whether it is better for the guest to be neutral or anionic. The enantiomeric resolution of neutral guests by ionic chiral solvating agents has rarely been studied, and when the guest is a carboxylic acid, it has usually been converted to the anion.¹⁰⁻¹³ Mosher's acid was used as a test compound as it enables detection by both ¹H and ¹⁹F NMR spectroscopy. In order to carry out a systematic study, the best performing chiral solvating agent was

used in the resolution of seven different carboxylate salts, to establish its applicability in resolving both aromatic and non-aromatic racemic carboxylic acids.

Scheme 1. Synthesis of (+)-dehydroabietylaminidazole (**1a**), and (+)-dehydroabietylaminidazolium (**1b**, **2**, and **4**) and (+)-dehydroabietylaminidazolinium (**3**) salts.

Experimental

General

All reagents and solvents were obtained from commercial suppliers (Sigma Aldrich) and were used without further purification unless otherwise stated. (+)-Dehydroabietylamine was purchased as 60% grade (Sigma-Aldrich) and purified by a method described in the literature¹⁵ with slight modifications (see below). Flash chromatography was performed on 40-63 mesh silica gel. Microwave syntheses were performed using the CEM Focused MicrowaveTM Synthesis System (Model Discover). Melting points were determined on a digital melting point apparatus (Büchi B 545). Optical rotations were determined on a digital polarimeter (JASCO DIP-1000) at 22 °C in trichloromethane as solvent. The exact mass measurements were performed by high-resolution mass spectrometry (Bruker MicroTOF LC) with electrospray ionisation (ESI).

Compound characterisation

NMR experiments were performed using Varian UNITY INOVA 500 and Varian Mercury Plus 300 instruments at 27 °C. ¹H NMR spectra were recorded with 4-16 transients, 4085-8000 Hz spectral width, and 1.9 s acquisition time at 500 MHz. ¹³C NMR spectra were recorded with 576-1500 transients, 20000-31446 Hz spectral width and 1.8 s acquisition time at 125 or 75 MHz. ¹⁹F NMR spectra were recorded with 16-32 transients, 19047 Hz spectral width, 5.0 s relaxation delay and 1.0 s acquisition time at 470 MHz. All 2D HSQC spectra (see supporting information) were recorded using the Varian UNITY INOVA 500 instrument with 4 transients, 128-300 increments, 8000-4085 Hz spectral widths in ¹H-dimension, 22955-31446 Hz spectral widths in ¹³C-dimension, 1.0-2.0 s relaxation delays, and 0.128 s acquisition time. TMS was used as the reference compound in NMR measurements. Chemical shift scale of ¹⁹F was fixed by applying absolute, indirect referencing by calculating the frequency position for 0.0 ppm in ¹⁹F chemical shift scale from the ¹H chemical shift scale. To differentiate the proton and carbon signals of aromatic and imidazolium and 2-imidazolium structures, subscript Ar (CH_{Ar}) is used for aromatic and im (CH_{im}) for imidazolium and 2-imidazolium.

Preparations

Purification of (+)-dehydroabietylamine Crude 60 % (+)-dehydroabietylamine (42.0 g) was dissolved in toluene (70.0 cm³) and ethanoic acid (9.65 g) in toluene (30.0 cm³) was slowly added. The salt was left to crystallise in the refrigerator. The product was

collected by filtration and washed with hexane (30.0 cm³). (+)-Dehydroabietylamine ethanoate was recrystallised from methanol. (+)-Dehydroabietylamine ethanoate (21.0 g) was dissolved in hot water and 10% aqueous NaOH solution (28.0 cm³) was added. (+)-Dehydroabietylamine was extracted with diethyl ether (50.0 cm³) and the organic phase was washed with water until neutral, and then dried over anhydrous sodium sulfate. The solvent was evaporated, and the resultant (+)-dehydroabietylamine was dried under vacuum to yield a white solid; yield 37.0 g, 88.2%; m.p. 44.2 °C (lit. 44-45 °C)¹⁶; [α]_D²⁵ +44.3480 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 0.89 (s, 3H, CH₃), 1.22 (s, 3H, CH₃), 1.22 (d, *J* = 7.0 Hz, 6H, 2×CH₃), 1.33 (m, 2H, CH₂), 1.39 (m, 1H, CHH), 1.52 (dd, *J* = -11.8, 3.3 Hz, 1H, CH), 1.69 (m, 2H, CH₂), 1.74 (m, 2H, CH₂), 2.30 (dt, *J* = -13.1, 1.7 Hz, 1H, CHH), 2.40 (d, *J* = -13.5 Hz, 1H, CHH), 2.61 (d, *J* = -13.5 Hz, 1H, CHH), 2.82 (sep. *J* = 7.0 Hz, CH), 2.88 (m, 2H, CH₂), 6.89 (d, *J* = 1.9 Hz, 1H, CH_{Ar}), 7.00 (dd, *J* = 8.1, 1.9 Hz, 1H, CH_{Ar}), 7.18 (d, *J* = 8.1 Hz, 1H, CH_{Ar}); ¹³C NMR (500 MHz, CDCl₃) δ ppm 18.78 (CH₂), 18.90 (CH₃), 18.90 (CH₂), 24.11 (CH₃), 24.13 (CH₃), 25.37 (CH₃), 30.31 (CH₂), 33.58 (CH), 35.36 (CH₂), 37.36 (C), 37.53 (C), 38.70 (CH₂), 45.00 (CH), 53.99 (CH₂), 123.96 (CH_{Ar}), 124.38 (CH_{Ar}), 126.94 (CH_{Ar}), 134.84 (C_{Ar}), 145.67 (C_{Ar}), 147.63 (C_{Ar}); HRMS-ESI (*m/z*) calc. for C₂₀H₃₂N [M + H]⁺ 286.2529, found 286.2540.

Synthesis of 1-dehydroabietylimidazole (1a) (+)-Dehydroabietylamine (5.0 g, 17.54 mmol, 1.0 eq) was dissolved in 2-propanol (10.0 cm³) and 25% aqueous ammonium hydroxide solution (2.70 cm³, 17.54 mmol, 1.0 eq) was added. A mixture of a 40% aqueous solution of glyoxal (2.17 cm³, 18.94 mmol, 1.08 eq) and 35% aqueous solution of formaldehyde (1.49 cm³, 18.94 mmol, 1.08 eq) in 2-propanol (20.0 cm³) was added dropwise to the reaction mixture which was kept at 80 °C for 4 h and left to stir at room temperature overnight. Water (20.0 cm³) was added to the reaction mixture, which was then extracted with diethyl ether (40.0 cm³). The organic phase was washed with water until neutral and dried over anhydrous magnesium sulfate. The organic phase was filtered and the solvent evaporated; the crude product was dried under vacuum, and recrystallised from a diethyl ether-pentane mixture. Yield 2.5 g, 41.7%; white solid; m.p. 107.6 °C; [α]_D²⁵ -25.9560 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 1.00 (s, 3H, CH₃), 1.21 (d, *J* = 6.92 Hz, 6H, 2×CH₃), 1.23 (s, 3H, CH₃), 1.28 (m, 1H, CHH), 1.33 (m, 1H, CHH), 1.35 (m, 1H, CH), 1.38 (m, 1H, CHH), 1.70 (m, 2H, CH₂), 1.87 (m, 2H, CH₂), 2.25 (dt, *J* = -13.1, 3.5 Hz, 1H, CHH), 2.81 (sep. *J* = 6.9 Hz, CH), 2.89 (m, 1H, CHH), 2.96 (ddd, *J* = -16.9, 6.7, 2.4 Hz, 1H, CHH), 3.70 (d, *J* = -14.0 Hz, 1H, CHH), 3.86 (d, *J* = -14.0 Hz, 1H, CHH), 6.83 (t, *J* = 1.1 Hz, 1H, CH_{im}), 6.88 (d, *J* = 2.1 Hz, 1H, CH_{Ar}), 6.97 (dd, *J* = 8.3, 2.1 Hz, 1H, CH_{Ar}), 6.99 (t, *J* = 1.1 Hz, 1H, CH_{im}), 7.12 (d, *J* = 8.3 Hz, 1H, CH_{Ar}), 7.38 (t, *J* = 1.1 Hz, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ ppm 18.59 (CH₂), 18.77 (CH₃), 19.40 (CH₂), 24.07 (CH₃), 24.09 (CH₃), 25.69 (CH₃), 29.94 (CH₂), 33.56 (CH), 36.72 (CH₂), 37.68 (C), 38.08 (C), 38.13 (CH₂), 45.06 (CH), 58.45 (CH₂), 121.12 (CH_{im}), 124.12 (CH_{Ar}), 124.23 (CH_{Ar}), 126.97 (CH_{Ar}), 128.81 (CH_{im}), 134.19 (C_{Ar}), 138.73 (CH_{im}), 145.90 (C_{Ar}), 146.84 (C_{Ar}); HRMS-ESI (*m/z*) calc. for C₂₃H₃₃N₂ [M + H]⁺ 337.2638, found 337.2635.

Synthesis of 1-(+)-dehydroabietylimidazolium bis{(trifluoromethyl)sulfonyl}amide (1b) Bistriflamidic acid (80 mg, 2.97 mM, 1.0 eq) was added to compound **1a** (0.10 g, 2.97 mmol, 1.0 eq) in dichloromethane (0.5 cm³) at 0 °C. After stirring the reaction mixture for 1 h at room temperature, water (3.0 cm³) was added, two layers separated, and the organic phase was washed with water (3×2.0 cm³). The organic solvent was evaporated and product dried in vacuum. Yield 0.18 g, 96.8%; amorphous solid at room temperature; [α]_D²⁵ -23.2360 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 1.05 (s, 3H, CH₃), 1.21 (d, *J* = 7.0 Hz, 6H, 2×CH₃), 1.24 (s, 3H, CH₃), 1.25 (m, 1H, CHH), 1.29 (m, 1H, CH), 1.31 (m, 1H, CHH), 1.41 (dt, *J* = -12.6, 2.9 Hz, 1H, CHH), 1.72 (m, 2H, CH₂), 1.89 (m, 2H, CH₂), 2.31 (dt, *J* = -12.7, 3.2 Hz, 1H, CHH), 2.82 (sep. *J* = 7.0 Hz, CH), 2.87 (m, 1H, CHH), 3.01 (ddd, *J* = -17.8, 8.4, 2.2 Hz, 1H, CHH), 4.06 (d, *J* = -14.3 Hz, 1H, CHH), 4.06 (d, *J* = -14.3 Hz, 1H, CHH), 6.90 (d, *J* = 1.9 Hz, 1H, CH_{Ar}), 6.99 (dd, *J* = 8.1, 1.9 Hz, 1H, CH_{Ar}), 7.13 (d, *J* = 8.1 Hz, 1H, CH_{Ar}), 7.14 (t, *J* = 1.5 Hz, 1H, CH_{im}), 7.33 (t, *J* = 1.5 Hz, 1H, CH_{im}), 8.40 (t, *J* = 1.5 Hz, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ /ppm 18.22 (CH₃), 18.31 (CH₂), 19.32 (CH₂), 24.03 (CH₃), 24.08 (CH₃), 25.57 (CH₃), 29.69 (CH₂), 33.57 (CH), 36.59 (CH₂), 37.76 (C), 37.97 (CH₂), 38.08 (C), 45.62 (CH), 60.92 (CH₂), 119.82 (q, *J* = 320.8, CF₃), 120.67 (CH_{im}), 123.28 (CH_{im}), 124.14 (CH_{Ar}), 124.33 (CH_{Ar}), 127.10 (CH_{Ar}), 133.90 (C_{Ar}), 136.04 (CH_{im}), 146.23 (C_{Ar}), 146.36 (C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₂₃H₃₃N₂]⁺ [M]⁺ 337.2638, found 337.2630, calc. for [C₂F₆NO₄S₂]⁻ 279.9167, found 279.9177.

Synthesis of 1,3-bisdehydroabietylimidazolium chloride (2a) Formaldehyde (35% aqueous solution; 0.14 cm³, 1.75 mmol, 1.0 eq) was added dropwise to (+)-dehydroabietylamine (1.0 g, 3.51 mmol, 2.0 eq) in toluene (10.0 cm³) at 0 °C and the reaction mixture was allowed to warm to room temperature. A mixture of aqueous hydrochloric acid (35%; 0.16 cm³, 1.75 mmol, 1.0 eq) and 40% glyoxal (0.20 cm³, 1.75 mmol, 1.0 eq) was added dropwise to the reaction mixture at 0 °C which was allowed warm to room temperature, and then heated for 24 h at 80 °C. The solvent was removed by evaporation and the crude product dried under vacuum, purified by column chromatography (1:9 methanol:CH₂Cl₂), and crystallised from a CH₂Cl₂:EtO₂CMe mixture. Yield 0.73 g, 64.5%; white solid; m.p. 220.5 °C; [α]_D²⁰ -66.4120 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 1.03 (s, 6H, 2×CH₃), 1.11 (m, 2H, 2×CHH), 1.15 (m, 2H, 2×CHH), 1.19 (s, 6H, 2×CH₃), 1.21 (d, *J* = 6.9 Hz, 12H, 4×CH₃), 1.24 (m, 2H, 2×CH), 1.43 (dt, *J* = -12.7, 2.8 Hz, 2H, 2×CHH), 1.53 (m, 2H, 2×CHH), 1.62 (m, 2H, 2×CHH), 1.88 (m, 2H, 2×CHH), 2.05 (m, 2H, 2×CHH), 2.19 (dt, *J* = -13.0, 3.2 Hz, 2H, 2×CHH), 2.81 (sep. *J* = 6.9 Hz, 2H, 2×CH), 2.89 (m, 2H, 2×CHH), 2.99 (dd, *J* = -17.4, 6.7 Hz, 2H, 2×CHH), 4.13 (d, *J* = -14.0 Hz, 2H, 2×CHH), 4.37 (d, *J* = -14.0 Hz, 2H, 2×CHH), 6.89 (d, *J* = 1.9 Hz, 2H, 2×CH_{Ar}), 6.96 (dd, *J* = 8.2, 1.9 Hz, 2H, 2×CH_{Ar}), 7.07 (d, *J* = 8.2 Hz, 2H, 2×CH_{Ar}), 7.11 (s, 2H, 2×CH_{im}), 10.78 (s, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ /ppm 18.22 (2×CH₃), 18.42 (2×CH₂), 19.22 (2×CH₂), 24.04 (2×CH₃), 24.08 (2×CH₃), 25.50 (2×CH₃), 29.72 (2×CH₂), 33.53 (2×CH), 36.61 (2×CH₂), 37.65 (2×C), 37.97 (2×CH₂), 38.19 (2×C), 45.43 (2×CH), 60.50 (2×CH₂), 122.75

(2×CH_{im}), 124.03 (2×CH_{Ar}), 124.09 (2×CH_{Ar}), 126.98 (2×CH_{Ar}), 134.09 (2×C_{Ar}), 140.99 (CH_{im}), 146.00 (2×C_{Ar}), 146.51 (2×C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₄₃H₆₁N₂]⁺ [M]⁺ 605.4829, found 605.4824.

Synthesis of *N,N'*-bisdehydroabietyl-1,2-diaminoethane (+)-Dehydroabietylamine (1.0 g, 3.51 mmol, 2.0 eq), 1,2-dibromoethane (0.15 cm³, 1.75 mmol, 1.0 eq) and Na₂CO₃ (0.18 g, 1.75 mmol, 1.0 eq) were added to a microwave tube with 2-propanol. The reaction mixture was microwave irradiated (110 W, at 110 °C) for 2 h. The solvent was evaporated and the solid triturated with diethyl ether, collected by filtration, and then mixed with diethyl ether (20.0 cm³) and aqueous sodium hydroxide (2.0 M, 10.0 cm³). The organic phase was washed with water until neutral and dried over anhydrous sodium sulfate. The organic phase was filtered and the solvent evaporated. The solid product was dried under vacuum and purified by flash chromatography (1:9 MeOH:DCM CH₂Cl₂). Yield 0.78 g 74.3%; white solid; m.p. 63.8 °C; [α]²²_D +43.3160 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ/ppm 0.91 (s, 6H, 2×CH₃), 1.20 (s, 6H, 2×CH₃), 1.23 (d, *J* = 7.0 Hz, 12H, 4×CH₃), 1.37 (m, 2H, 2×CHH), 1.38 (m, 4H, 2×CH₂), 1.57 (dd, *J* = -12.3, 2.7 Hz, 2H, 2×CH), 1.60 (m, 4H, 2×CH₂), 1.71 (m, 2H, 2×CHH), 1.75 (m, 2H, 2×CHH), 2.23 (dt, *J* = -12.8, 3.3 Hz, 2H, 2×CHH), 2.32 (d, *J* = -11.8 Hz, 2H, 2×CHH), 2.51 (d, *J* = -11.8 Hz, 2H, 2×CHH), 2.70 (s, 4H, 2×CH₂), 2.82 (sep. *J* = 7.0 Hz, 2H, 2×CH), 2.88 (m, 4H, 2×CH₂), 6.87 (d, *J* = 1.7 Hz, 2H, 2×CH_{Ar}), 6.98 (dd, *J* = 8.1, 1.6 Hz, 2H, 2×CH_{Ar}), 7.16 (d, *J* = 8.1 Hz, 2H, 2×CH_{Ar}); ¹³C NMR (500 MHz, CDCl₃) δ/ppm 18.98 (4×CH₂), 19.35 (2×CH₃), 24.14 (4×CH₃), 25.47 (2×CH₃), 30.46 (2×CH₂), 33.58 (2×CH), 36.39 (2×CH₂), 37.18 (2×C), 37.55 (2×C), 38.58 (2×CH₂), 45.62 (2×CH), 50.02 (2×CH₂), 61.61 (2×CH₂), 123.91 (2×CH_{Ar}), 124.41 (2×CH_{Ar}), 126.89 (2×CH_{Ar}), 134.88 (C_{Ar}), 145.54 (2×C_{Ar}), 147.64 (2×C_{Ar}); HRMS-ESI (*m/z*) calc. for C₄₂H₆₅N₂ [M + H]⁺ 597.5142, found 597.5132.

Synthesis of 1,3-bisdehydroabietyl-2-dihydroimidazolinium tetrafluoroborate (3a) A microwave tube was loaded with *N,N'*-bisdehydroabietyl-1,2-diaminoethane (0.5 g, 0.84 mmol, 1.0 eq), triethylorthoformate (0.14 cm³, 0.84 mmol, 1.0 eq), ammonium tetrafluoroborate (88 mg, 0.84 mmol, 1.0 eq) and 2-propanol (1.0 cm³). The reaction mixture was irradiated (140 W, at 110 °C) for 40 min. The solvent was removed by evaporation and diethyl ether (5.0 cm³) was added. The mixture was then filtered and the resultant solid dried under reduced pressure followed by recrystallisation from a methanol-ethanenitrile mixture. Yield; 0.41 g, 66.8%; white solid; m.p. 210.4 °C; [α]²²_D -45.1400 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ/ppm 0.97 (s, 6H, 2×CH₃), 1.20 (s, 6H, 2×CH₃), 1.21 (m, 2H, 2×CHH), 1.22 (d, *J* = 6.9 Hz, 12H, 4×CH₃), 1.30 (m, 2H, 2×CH), 1.31 (m, 2H, 2×CHH), 1.50 (dt, *J* = -13.1 Hz, 2H, 2×CHH), 1.63 (m, 4H, 2×CH₂), 1.76 (m, 2H, 2×CHH), 1.84 (m, 2H, 2×CHH), 2.28 (dt, *J* = -13.5, 3.3 Hz, 2H, 2×CHH), 2.79 (m, 2H, 2×CHH), 2.82 (sep. *J* = 6.9 Hz, 2H, 2×CH), 2.97 (m, 2H, 2×CHH), 3.40 (d, *J* = -14.8 Hz, 2H, 2×CHH), 3.44 (d, *J* = -14.8 Hz, 2H, 2×CHH), 4.03 (m, 4H, 2×CH₂), 6.88 (d, *J* = 2.0 Hz, 2H, 2×CH_{Ar}), 6.98 (dd, *J* = 8.2, 2.0 Hz, 2H, 2×CH_{Ar}), 7.12 (d, *J* = 8.2 Hz, 2H, 2×CH_{Ar}), 7.91 (m, 1H, CH); ¹³C NMR (500 MHz, CDCl₃) δ/ppm 18.26 (2×CH₂), 18.45 (2×CH₃), 18.67 (2×CH₂), 23.81 (2×CH₃), 23.87 (2×CH₃), 25.28 (2×CH₃), 29.54 (2×CH₂), 33.32 (2×CH), 36.65 (2×CH₂), 37.40 (2×C), 37.91 (2×CH₂), 38.21 (2×C), 45.29 (2×CH), 52.54 (2×CH₂), 59.55 (2×CH₂), 123.92 (2×CH_{Ar}), 123.98 (2×CH_{Ar}), 126.78 (2×CH_{Ar}), 133.78 (C_{Ar}), 145.80 (2×C_{Ar}), 146.45 (2×C_{Ar}), 161.75 (CH); HRMS-ESI (*m/z*) calc. for [C₄₃H₆₃N₂]⁺ [M]⁺ 607.4986, found 607.4995.

Synthesis of 3-benzyl-1-dehydroabietylimidazolium bromide (4a) (+)-Dehydroabietylimidazole (0.3 g, 0.891 mmol, 1.0 eq), benzyl bromide (0.168 g, 0.117 cm³, 0.981 mmol, 1.1 eq) and CHCl₃ (0.3 cm³) were added to an microwave tube. The reaction mixture was irradiated (110 W, at 110 °C) for 1h. The product was quenched with diethyl ether, filtered and dried under vacuum. Yield 0.42 g, 93.7 %; white solid; m.p. 152.9 °C; [α]²²_D -27.0920 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ/ppm 1.07 (s, 3H, CH₃), 1.22 (d, *J* = 6.9 Hz, 6H, 2×CH₃), 1.22 (s, 3H, CH₃), 1.23 (m, 1H, CH), 1.28 (m, 1H, CHH), 1.30 (m, 1H, CHH), 1.48 (m, 1H, CHH), 1.71 (m, 2H, CH₂), 1.89 (m, 1H, CHH), 2.27 (dt, *J* = -13.0 Hz, 1H, CHH), 2.62 (dd, *J* = -13.5, 7.6 Hz, 1H, CHH), 2.82 (sep. *J* = 6.9 Hz, CH), 2.82 (m, 1H, CHH), 3.01 (dt, *J* = -17.6, 6.3 Hz, 1H, CHH), 4.16 (d, *J* = -14.1 Hz, 1H, CHH), 4.26 (d, *J* = -14.1 Hz, 1H, CHH), 5.60 (s, 2H, CH₂), 6.89 (d, *J* = 1.2 Hz, 1H, CH_{Ar}), 6.98 (dd, *J* = 8.2, 1.2 Hz, 1H, CH_{Ar}), 7.11 (d, *J* = 8.2 Hz, 1H, CH_{Ar}), 7.15 (m, 1H, CH_{im}), 7.21 (m, 1H, CH_{im}), 7.34 (m, 3H, 3×CH_{Ar}), 7.46 (m, 2H, 2×CH_{Ar}), 10.75 (m, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ/ppm 18.32 (CH₂), 18.46 (CH₃), 19.31 (CH₂), 24.05 (CH₃), 24.09 (CH₃), 25.56 (CH₃), 29.84 (CH₂), 33.55 (CH), 36.60 (CH₂), 37.75 (C), 37.98 (CH₂), 38.14 (C), 45.49 (CH), 53.50 (CH₂), 60.86 (CH₂), 121.09 (CH_{im}), 123.74 (CH_{im}), 124.07 (CH_{Ar}), 124.21 (CH_{Ar}), 127.12 (CH_{Ar}), 129.15 (CH_{Ar}), 129.58 (CH_{Ar}), 129.64 (CH_{Ar}), 132.99 (C_{Ar}), 134.11 (C_{Ar}), 138.78 (CH_{im}), 146.09 (C_{Ar}), 146.47 (C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₃₀H₃₉N₂]⁺ [M]⁺ 427.3108, found 427.3118.

Synthesis of guests

N-Acetylation of phenylalanine was performed according to literature.¹⁷ Preparation of tetrabutylammonium salts of acids was performed by adding tetrabutylammonium hydroxide (1.0 M in methanol, 1.0 eq) to the racemic acid (1.0 eq) in methanol. After stirring for 3 h, the solvent was removed by evaporation and the product was dried in vacuum.

General procedure for anion exchange

Anion exchange reactions were performed according to literature.^{14a} Li[NTf₂] or ammonium tetrafluoroborate solution (1.0 M, 1.0 eq) was added to the chiral solvating agent (1.0 eq, in dichloromethane) at room temperature and stirred for 1 h. The phases were separated by gravity and the organic phase was washed with water (3×10 cm³). The organic phase was concentrated and dried under vacuum.

1,3-Bisdehydroabietylimidazolium tetrafluoroborate (2b) Yield 0.21 g 94.2 %; white solid; m.p. 186.9 °C (recryst. from CH₂Cl₂:EtOCOME); [α]²⁰_D -67.5760 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 0.99 (s, 6H, 2×CH₃), 1.03 (m, 2H, 2×CHH), 1.10 (m, 2H, 2×CHH), 1.14 (m, 2H, 2×CH), 1.18 (s, 6H, 2×CH₃), 1.21 (d, *J* = 7.0 Hz, 12H, 4×CH₃), 1.35 (dt, *J* = -12.6, 3.2 Hz, 2H, 2×CHH), 1.46 (m, 2H, 2×CHH), 1.60 (d, *J* = -13.6, 3.2 Hz, 2H, 2×CHH), 1.84 (m, 2H, 2×CHH), 1.98 (m, 2H, 2×CHH), 2.14 (dt, *J* = -13.1, 3.6 Hz, 2H, 2×CHH), 2.82 (sep. *J* = 7.0 Hz, 2H, 2×CH), 2.86 (m, 2H, 2×CHH), 2.98 (dd, *J* = -17.5, 6.7 Hz, 2H, 2×CHH), 4.09 (d, *J* = -13.2 Hz, 2H, 2×CHH), 4.16 (d, *J* = -13.2 Hz, 2H, 2×CHH), 6.90 (d, *J* = 1.9 Hz, 2H, 2×CH_{Ar}), 6.97 (dd, *J* = 8.2, 1.9 Hz, 2H, 2×CH_{Ar}), 7.06 (d, *J* = 8.2 Hz, 2H, 2×CH_{Ar}), 7.10 (d, *J* = 1.6 Hz, 2H, 2×CH_{im}), 9.20 (s, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ /ppm 18.21 (2×CH₃), 18.35 (2×CH₂), 18.99 (2×CH₂), 24.06 (2×CH₃), 24.09 (2×CH₃), 25.51 (2×CH₃), 29.64 (2×CH₂), 33.54 (2×CH), 36.38 (2×CH₂), 37.61 (2×C), 37.95 (2×CH₂), 38.06 (2×C), 45.29 (2×CH), 60.27 (2×CH₂), 123.12 (2×CH_{im}), 124.06 (4×CH_{Ar}), 126.96 (2×CH_{Ar}), 134.10 (2×C_{Ar}), 139.70 (CH_{im}), 145.95 (2×C_{Ar}), 146.53 (2×C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₄₃H₆₁N₂]⁺ [M]⁺ 605.4829, found 605.4837.

1,3-Bisdehydroabietylimidazolium bis{(trifluoromethyl)sulfonyl}amide (2c) Yield 0.25 g; 92.6 %; white solid; m.p. 199.0 °C (recryst. from CH₂Cl₂:pentane); [α]²²_D -31.8200 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 0.99 (s, 6H, 2×CH₃), 1.04 (m, 2H, 2×CHH), 1.05 (m, 2H, 2×CHH), 1.16 (m, 2H, 2×CH), 1.19 (s, 6H, 2×CH₃), 1.21 (d, *J* = 6.9 Hz, 12H, 4×CH₃), 1.36 (dt, *J* = -12.3 Hz, 2H, 2×CHH), 1.49 (m, 2H, 2×CHH), 1.63 (m, 2H, 2×CHH), 1.90 (m, 4H, 2×CH₂), 2.17 (dt, *J* = -12.8, 2.3 Hz, 2H, 2×CHH), 2.82 (sep. *J* = 6.9 Hz, 2H, 2×CH), 2.84 (m, 2H, 2×CHH), 3.01 (ddd, *J* = -17.3, 6.0, 1.7 Hz, 2H, 2×CHH), 4.09 (d, *J* = -13.9 Hz, 2H, 2×CHH), 4.16 (d, *J* = -13.9 Hz, 2H, 2×CHH), 6.89 (d, *J* = 1.8 Hz, 2H, 2×CH_{Ar}), 6.97 (dd, *J* = 8.1, 1.8 Hz, 2H, 2×CH_{Ar}), 7.06 (d, *J* = 8.1 Hz, 2H, 2×CH_{Ar}), 7.10 (s, 2H, 2×CH_{im}), 8.62 (s, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ /ppm 17.92 (2×CH₂), 18.11 (2×CH₃), 18.81 (2×CH₂), 23.83 (2×CH₃), 23.86 (2×CH₃), 25.26 (2×CH₃), 29.32 (2×CH₂), 33.33 (2×CH), 36.30 (2×CH₂), 37.41 (2×C), 37.69 (2×CH₂), 37.94 (2×C), 44.98 (2×CH), 60.45 (2×CH₂), 119.95 (q, *J* = 321.0, CF₃), 123.22 (2×CH_{im}), 123.86 (2×CH_{Ar}), 123.97 (2×CH_{Ar}), 126.76 (2×CH_{Ar}), 133.59 (2×C_{Ar}), 138.00 (CH_{im}), 145.92 (2×C_{Ar}), 146.10 (2×C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₄₃H₆₁N₂]⁺ [M]⁺ 605.4829, found 605.4814, calc. for [C₂F₆NO₄S₂]⁻ 279.9167, found 279.9160.

1,3-Bisdehydroabietyl-2-dihydroimidazolinium bis{(trifluoromethyl)sulfonyl}amide (3b) Yield 0.45 g; 82.7%; white solid; m.p. 88.8 °C; [α]²²_D -31.8520 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 0.978 (s, 6H, 2×CH₃), 1.17 (m, 2H, 2×CHH), 1.21 (s, 6H, 2×CH₃), 1.22 (d, *J* = 6.9 Hz, 12H, 4×CH₃), 1.29 (m, 2H, 2×CHH), 1.30 (m, 2H, 2×CH), 1.47 (dt, *J* = -12.3, 3.0 Hz, 2H, 2×CHH), 1.62 (m, 4H, 2×CH₂), 1.75 (m, 2H, 2×CHH), 1.84 (m, 2H, 2×CHH), 2.29 (dt, *J* = -13.2, 3.2 Hz, 2H, 2×CHH), 2.78 (m, 2H, 2×CHH), 2.82 (sep. *J* = 6.9 Hz, 2H, 2×CH), 2.99 (dd, *J* = -17.1, 7.0 Hz, 2H, 2×CHH), 3.35 (d, *J* = -14.8 Hz, 2H, 2×CHH), 3.44 (d, *J* = -14.8 Hz, 2H, 2×CHH), 4.03 (m, 4H, 2×CH₂), 6.89 (d, *J* = 1.7 Hz, 2H, 2×CH_{Ar}), 6.99 (dd, *J* = 8.3, 1.7 Hz, 2H, 2×CH_{Ar}), 7.12 (d, *J* = 8.3 Hz, 2H, 2×CH_{Ar}), 7.75 (m, 1H, CH); ¹³C NMR (500 MHz, CDCl₃) δ /ppm 18.43 (2×CH₂), 18.65 (2×CH₃), 18.96 (2×CH₂), 24.06 (2×CH₃), 24.12 (2×CH₃), 25.51 (2×CH₃), 29.70 (2×CH₂), 33.58 (2×CH), 37.05 (2×CH₂), 37.65 (2×C), 38.14 (2×CH₂), 38.56 (2×C), 45.54 (2×CH), 52.78 (2×CH₂), 59.89 (2×CH₂), 119.96 (q, *J* = 320.6, CF₃), 124.16 (2×CH_{Ar}), 124.31 (2×CH_{Ar}), 127.03 (2×CH_{Ar}), 133.87 (C_{Ar}), 146.16 (2×C_{Ar}), 146.56 (2×C_{Ar}), 161.37 (CH); HRMS-ESI (*m/z*) calc. for [C₄₃H₆₃N₂]⁺ [M]⁺ 607.4986, found 607.4967, calc. for [C₂F₆NO₄S₂]⁻ 279.9167, found 279.9157.

3-Benzyl-1-dehydroabietylimidazolium tetrafluoroborate (4b) Yield 0.099 g 97.5%; white solid; m.p. 113.4 °C; [α]²²_D -29.9880 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ ppm 1.01 (s, 3H, CH₃), 1.19 (m, 1H, CH), 1.20 (s, 3H, CH₃), 1.22 (d, *J* = 6.8 Hz, 6H, 2×CH₃), 1.23 (m, 1H, CHH), 1.28 (m, 1H, CHH), 1.40 (dt, *J* = -12.5 Hz, 1H, CHH), 1.68 (m, 2H, CH₂), 1.87 (m, 2H, CH₂), 2.26 (dt, *J* = -13.4 Hz, 1H, CHH), 2.74 (m, 1H, CHH), 2.82 (sep. *J* = 6.8 Hz, 1H, CH), 2.96 (dd, *J* = -13.5, 6.1 Hz, 1H, CHH), 4.04 (d, *J* = -14.3 Hz, 1H, CHH), 4.11 (d, *J* = -14.3 Hz, 1H, CHH), 5.36 (s, 2H, CH₂), 6.88 (d, *J* = 1.8 Hz, 1H, CH_{Ar}), 6.98 (dd, *J* = 8.1, 1.8 Hz, 1H, CH_{Ar}), 7.11 (d, *J* = 8.1 Hz, 1H, CH_{Ar}), 7.15 (m, 1H, CH_{im}), 7.18 (m, 1H, CH_{im}), 7.33 (m, 3H, 3×CH_{Ar}), 7.38 (m, 2H, 2×CH_{Ar}), 9.07 (m, 1H, CH_{im}); ¹³C NMR (500 MHz, CDCl₃) δ /ppm 18.17 (CH₃), 18.34 (CH₂), 19.12 (CH₂), 24.08 (CH₃), 24.12 (CH₃), 25.57 (CH₃), 29.75 (CH₂), 33.58 (CH), 36.38 (CH₂), 37.74 (C), 37.97 (C), 38.00 (CH₂), 45.62 (CH), 53.60 (CH₂), 61.00 (CH₂), 121.50 (CH_{im}), 124.11 (CH_{im}), 124.22 (CH_{Ar}), 124.26 (CH_{Ar}), 127.12 (CH_{Ar}), 129.08 (CH_{Ar}), 129.63 (CH_{Ar}), 129.66 (CH_{Ar}), 132.92 (C_{Ar}), 134.11 (C_{Ar}), 137.43 (CH_{im}), 146.07 (C_{Ar}), 146.52 (C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₃₀H₃₉N₂]⁺ [M]⁺ 427.3108, found 427.3118.

3-Benzyl-1-dehydroabietylimidazolium bis{(trifluoromethyl)sulfonyl}amide (4c) Yield 0.13 g 92.7%; amorphous solid at room temperature; [α]²²_D -25.3600 (c = 10.0 mg/cm³, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ /ppm 1.02 (s, 3H, CH₃), 1.18 (m, 1H, CHH), 1.19 (m, 1H, CH), 1.22 (d, *J* = 6.9 Hz, 6H, 2×CH₃), 1.22 (s, 3H, CH₃), 1.29 (m, 1H, CHH), 1.41 (m, 1H, CHH), 1.71 (m, 2H, CH₂), 1.87 (m, 2H, CH₂), 2.29 (dt, *J* = -12.4 Hz, 1H, CHH), 2.73 (m, 1H, CHH), 2.82 (sep. *J* = 6.9 Hz, 1H, CH), 2.96 (dt, *J* = 17.1, 3.7 Hz, 1H, CHH), 4.06 (d, *J* = -14.1 Hz, 1H, CHH), 4.10 (d, *J* = -14.1 Hz, 1H, CHH), 5.34 (s, 2H, CH₂), 6.88 (d, *J* = 1.6 Hz, 1H, CH_{Ar}), 6.99 (dd, *J* = 8.3, 1.6 Hz, 1H, CH_{Ar}), 7.12 (d, *J* = 8.3 Hz, 1H, CH_{Ar}), 7.14 (m, 2H, 2×CH_{im}), 7.24 (m, 1H, CH_{Ar}), 7.32 (m, 2H, 2×CH_{Ar}), 7.37 (m, 2H, 2×CH_{Ar}), 8.80 (m, 1H, CH_{im}); ¹³C NMR (300 MHz, CDCl₃) δ /ppm 18.21 (CH₃), 18.30 (CH₂), 19.14 (CH₂), 24.06 (CH₃), 24.10 (CH₃), 25.58 (CH₃), 29.68 (CH₂), 33.58 (CH), 36.52 (CH₂), 37.77 (C), 37.99 (C), 38.07 (CH₂), 45.46 (CH), 53.92 (CH₂), 61.12 (CH₂), 119.96 (q, *J* = 320.6, CF₃), 121.45 (CH_{im}), 124.11 (CH_{im}), 124.22 (CH_{Ar}), 124.31 (CH_{Ar}), 127.14 (CH_{Ar}), 129.00 (CH_{Ar}), 129.82 (CH_{Ar}), 129.99 (CH_{Ar}), 132.16 (C_{Ar}), 133.93 (C_{Ar}), 137.16 (CH_{im}), 146.22 (C_{Ar}), 146.38 (C_{Ar}); HRMS-ESI (*m/z*) calc. for [C₃₀H₃₉N₂]⁺ [M]⁺ 427.3108, found 427.3122; calc. for [C₂F₆NO₄S₂]⁻ 279.9167, found 279.9167.

Results and discussion

The syntheses of (+)-1-dehydroabietylimidazole (**1a**) and the nine derived imidazolium salts (**1b-4c**) were performed as shown in Scheme 1. To obtain **1a**, (+)-dehydroabietylamine was treated with aqueous NH₃, glyoxal and aqueous formaldehyde in 2-propanol at 80 °C (41%). The salt **1b** was formed (96%) from **1a** by reaction with HNTf₂ in CH₂Cl₂ at 0 °C. Compound **2a** was obtained from (+)-dehydroabietylamine, glyoxal, aqueous formaldehyde and aqueous hydrochloric acid (64%) in toluene. **3a** was prepared *via* *N,N'*-bisdehydroabietyl-1,2-diaminoethane, in a one-pot reaction from (+)-dehydroabietylamine, 1,2-dibromoethane and Na₂CO₃ in 2-propanol with microwave heating (74%), followed by the addition of CH(OEt)₃ and [NH₄][BF₄] in 2-propanol (66%). For improved shielding ability, **1a** was quaternised with benzyl bromide under microwave irradiation to give **4a**. It is known that more delocalised and bulky anions generally enhance binding between the cationic chiral solvating agent and (ionic or molecular) chiral substrate due to weaker binding between the cation and anion of chiral solvating agent.⁸ To tune the binding properties of **2a**, **3a** and **4a**, anion exchange was performed with [NH₄][BF₄] and Li[NTf₂] to obtain **2b-c**, **3b** and **4b-c** in high yield. The delocalisation and increased size of the anion also affect the physical properties of the ionic chiral solvating agents.⁸ For instance, the melting points of **4a**, **4b** and **4c** decrease when the bulkiness and delocalisation of anion increase (m.p. of Br > [BF₄] > [NTf₂]).

The chiral discrimination of racemic carboxylic acids and their respective carboxylate anions by (+)-1-dehydroabietylimidazole (**1a**) and its imidazolium salt derivatives (**1b-4c**) was examined with Mosher's acid [**5**; F₃CC(OCH₃)(Ph)COOH] and its tetrabutylammonium ([N₄₄₄₄]⁺) salt (**6**). The effect of the concentration of the chiral solvating agent was also investigated, since it is known that higher concentrations generally enhance the enantiomeric resolution between *R* and *S* enantiomers ($\Delta\delta$).^{4,5} Since polar solvents can dissolve salts, and protic solvents may interfere in hydrogen bond formation,^{13a} CDCl₃ was chosen as a solvent for the NMR studies, performed by dissolving the chiral solvating agent (1.0 or 2.0 eq) in a stock solution containing **5** or **6** (0.5 cm³; 1.0 eq, 22.0 mM). According to the results obtained from the NMR experiments (Table 1 and Fig. 1), the chiral solvating agents **1b-4c** resolved the enantiomers of **6** very efficiently (11.4-49.9 Hz). The best results were obtained with **2c** (0.11 ppm, 49.8 Hz). Also the enantiomers of **5** were resolved, but with a $\Delta\delta$ less than that with **6**. Only **1a** gave notably better discrimination for **5** (19.3 Hz) compared to **1b-4c** (0.88-7.0 Hz). This indicates that resolution using **1b-4c** is highly dependent on the ionic nature of the guest and *vice versa* in the case of **5**. Although ionic hosts (**1b-3b** and **4c**) were able to discriminate **5**, the neutral **1a** failed to discriminate **6**, making the ionic chiral solvating agents more versatile than a neutral one as the former also discriminate neutral species. For **6** and **5**, $\Delta\delta$ was found to be larger in the ¹⁹F NMR spectra than in the ¹H NMR spectra. The ionic **1b-4c** gave larger resolutions in ¹H NMR spectra in the case of **5** compared to **6**. This may be due to a different host-guest complex structure formed between the neutral guest and the ionic host, compared to situation when both are ionic. The increase of chiral solvating agent concentration to 2.0 eq. did not cause a significant increase in $\Delta\delta$ (~ 0.0-8.0 Hz). Also, in some cases (**1b**, **2c**, **3b** and **4c**), the resolution was decreased due to an increased host concentration.

Table 1. The ¹H and ¹⁹F NMR chemical shift differences ($\Delta\delta$) between the *R* and *S* enantiomers of racemic Mosher's acid (**5**) and its tetrabutylammonium salt (**6**) in the presence of various (+)-dehydroabietylimidazole chiral solvating agents (500 MHz) in CDCl₃ at 27 °C.

<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <chem>COc1ccccc1C(C)(C)C(=O)O</chem> 5 </div> <div style="text-align: center;"> $[N_{4444}]^{\oplus}$ </div> <div style="text-align: center;"> $\left[\text{COc1ccccc1C(C)(C)C(=O)O} \right]^{\ominus}$ 6 </div> </div>					
Host:	5: $\Delta\delta$ppm; (Hz)		6: $\Delta\delta$ppm; (Hz)		
Guest	^1H (OCH ₃)	^{19}F (CF ₃)	^1H (OCH ₃)	^{19}F (CF ₃)	
1a	1:1	0.0092 (4.6)	0.031 (14.8)	0.000	0.000
	2:1	0.011 (5.7)	0.041 (19.3)	0.000	0.000
1b	1:1	0.002 (0.99)	0.000	0.0044 (2.2)	0.024 (11.4)
	2:1	0.000	0.000	0.0042 (2.1)	0.026 (12.2)
2a	1:1	0.0056 (2.8)	0.000	0.000	0.074 (35.0)
	2:1	0.0091 (4.5)	0.000	0.000	0.080 (37.7)
2b	1:1	0.0071 (3.5)	0.000	0.000	0.092 (43.5)
	2:1	0.0099 (5.0)	0.000	0.000	0.102 (47.9)
2c	1:1	0.002 (1.0)	0.000	0.0029 (1.5)	0.110 (49.8)
	2:1	0.000	0.000	0.0061 (3.0)	0.110 (49.9)
3a	1:1	0.000	0.007 (3.3)	0.000	0.060 (28.1)
	2:1	0.000	0.015 (7.0)	0.000	0.077 (36.4)
3b	1:1	0.0019 (1.0)	0.000	0.000	0.065 (30.6)
	2:1	0.000	0.000	0.000	0.074 (34.7)
4a	1:1	0.000	0.000	0.000	0.028 (13.4)
	2:1	0.000	0.000	0.000	0.033 (15.7)
4b	1:1	0.000	0.000	0.000	0.034 (15.7)
	2:1	0.000	0.000	0.000	0.036 (17.0)
4c	1:1	0.0017 (0.8)	0.000	0.000	0.034 (15.8)
	2:1	0.000	0.000	0.000	0.032 (15.3)

Figure 1. NMR spectra [^1H (OCH₃) and ^{19}F (CF₃)] of **5** (A) and **6** (B) from the resolution of enantiomers with chiral solvating agents **1a-4c** in 1:1 and 2:1 host:guest ratio.

To determine which features affect the resolution of **5** and **6** by an ionic host (**1b-4c**), the effect of the structure of the cation and its counter anion were examined. The discrimination of enantiomers of **6** was enhanced by a bulky chiral substituent on the imidazolium N-3, an aromatic ionic unit and an anion with a more delocalised charge ([NTf₂]⁻ vs. Cl⁻). In the case of **5**, resolution was enhanced by a bulky substituent at the N-3 site, a non-aromatic ionic unit and an anion with a more localised charge (Cl⁻ vs. [BF₄]⁻). For example, **1b**, lacking a substituent at N-3, resolves the enantiomers of **6** less efficiently than **4c**, which has a benzyl

group as the N-3 substituent. This indicates that the presence and nature of an imidazolium N-3 substituent is important for the resolution. When comparing **4a-c** with **3a,b** and **2a-c**, where the imidazolium nucleus carries two (+)-dehydroabietyl groups, the discrimination is distinctly improved. An additional contribution to binding comes from hydrophobic and π - π stacking effects due to the substituents on the imidazolium unit. This can be seen from the simplified models in Figure 2, illustrating a tentative complex structure. On comparing **3a,b** and **2a-c**, it is clearly seen that the aromaticity of the ionic centre has a beneficial influence on $\Delta\delta$ (e.g. **2c** vs **3b**). Similar behaviour was noted with **5**, and also in this case a bulky side chain at N-3 enhanced the resolution. The non-aromatic ionic centre (**3a**, 7.0 Hz) was noted to give a better resolution for **5** than for an aromatic one (**2a-2c**, 1.0-5.0 Hz).

No explicit counter anion effects on the discrimination of molecular guests could be seen. In a 1:1 stoichiometry, [NTf₂]⁻ (**2c**, **3b** and **4c**) gave the best resolution, as non-hydrogen-bonding anions (such as [NTf₂]⁻) allow bonding between the host and the carboxylate to occur more efficiently due to its 'loose' association with the host cation. However, when the concentration was increased, [BF₄]⁻ gave slightly better results in the case of **3a** and **4a**. This phenomenon may be due to aggregation between the host and guest due to the increased concentration of host. In the case of **5**, the effect of a counter anion was also noted, although in this case the delocalisation of charge in the anion did not seem to increase resolution. An anion with a more localised charge favoured resolution, and among those the size of anion (Cl⁻ vs. [BF₄]⁻) seemed to play a crucial role.

As **2c** gave the best resolution (49.9 Hz), its enantiomeric discrimination power was further investigated by titration to find the optimum conditions for complexation. It is important to establish the structure of the complex in order to evaluate how much chiral solvating agent will be needed for optimal resolution. It also helps to evaluate if it is practical to increase the amount of host over the stoichiometric amount. A guest solution of **6** (0.5 cm³, 2.0 mM) was measured into an NMR tube and titrated with 0.5 mm³ doses of a host solution of **2c** (46.6 mM). Figures 3A and 4 show the chemical shifts of *S* and *R* enantiomers as a function of host concentration. Also, the change in the chemical shifts of enantiomers was determined (Fig. 3B) from the titration experiment. The $\Delta\delta$ was not large enough in ¹H NMR spectra (Fig. 4) for a reliable indication of complexation and only data from ¹⁹F NMR spectra were used. The $\Delta\delta$ change between *S* and *R* enantiomers as a function of host concentration (Fig 3C) suggest that maximal resolution is obtained when the concentrations of host and guest are the same (2.0 mM, 1.0 eq), corresponding to a 1:1 complexation. Also a Job's plot¹⁸ based on data obtained from a titration experiment (Fig. 3D) confirmed the 1:1 complex stoichiometry.

Figure 2. A model illustrating how the cation of **2c** may interact with (left) a carboxylate anion and (right) Mosher's carboxylate. Hydrogen atoms have been omitted for clarity.

Figure 3. (A) The chemical shifts of *S* (+) and *R* (Δ) enantiomers of **6** (*c* = 2.0 mM); (B) the change of chemical shift of *R* and *S* enantiomers of **6**; (C) $\Delta\delta$ between *R* and *S* enantiomers of **6** as a function of concentration of **2c**; (D) Job's plot ([*H*] = the concentration of host, [*G*] = the concentration of guest).

Table 2. Determination of chiral discrimination of seven racemic tetrabutylammonium carboxylate salts in the presence **2c**, using ¹H NMR (500 MHz, CDCl₃, 27 °C) spectroscopy.

Compd.	[N ₄₄₄₄] ⁺ salt of racemic carboxylic acid	$\Delta\delta$	
		ppm	Hz
7		Me	0.000 0.0
		CHMe ₂	0.0096 4.8
		H	0.0087 4.4
		CH ₂	0.006 3.0
8		Me	0.0065 3.2
		H	0.0047 2.3
9		H	0.0077 3.9
10		Me	0.000 0.0
		H	0.0055 2.8
11		Me	0.041 20.6
		H	0.000 0.0
		NH	0.019 9.7
12		Me	0.0021 1.1
		H	0.0033 1.6
13		H	0.0044 2.19

Conclusions

New (+)-dehydroabietylimidazolium chiral solvating agents were synthesised and tested for the resolution of Mosher's acid (**5**) and its tetrabutylammonium salt (**6**). All nine cationic chiral solvating agents resolved **6** highly efficiently. The best resolution of the enantiomers of **6** was obtained with **2c**. The enantiomers of **5** were also resolved and gave better resolution in ¹H NMR spectra compared to **6**, which was better resolved in ¹⁹F NMR spectra. The behaviour of **6** in resolution was further studied by titration, which indicated a 1:1 complexation between the host and guest. Further studies also showed that cationic chiral solvating agents such as **2c** can be expediently used for the determination of enantiomeric excesses of other chiral racemic carboxylates. The enantiomeric resolution of seven racemic α -substituted carboxylic acids was carried out with **2c**, showing that acids containing polar group(s) at the α -site can be resolved efficiently. Additionally, there is no strict requirement for the presence of an aryl substituent in the carboxylic acid, allowing a wider diversity of the guest substrates. The new (+)-dehydroabietylimidazolium chiral solvating agents constitute a biorenewable approach to *ee* determination.

Supplementary material

Spectral data of ^1H and ^{13}C NMR spectra and other spectra of synthesised products **1a-4c** are available on the Journal's website.

Acknowledgements

We thank Dr. S. Heikkinen for his help with NMR spectroscopic studies, and QUILL and its staff for the opportunity for TL and KW to visit their laboratory.

Notes and references

- [1] S. Witkowski and I. Wawer, in *Stereoselective Synthesis of Drugs and Natural Products* (Eds.: V. Andrushko and N. Andrushko), John Wiley & Sons, Inc., Hoboken, New Jersey, **2014**, pp. 1483-1504.
- [2] H. Bergmann, B. Grosch, S. Sitterberg and T. Bach, *J. Org. Chem.*, **2004**, *69*, 970-973.
- [3] (a) K. S. Heo, M. H. Hyun, Y. J. Cho and J. J. Ryoo, *Chirality*, **2011**, *23*, 281-286.
(b) S. H. Grimm, L. Allmendinger, G. Hoefner and K. T. Wanner, *Chirality*, **2013**, *25*, 923-933.
- [4] G. Uccello-Barretta and F. Balzano, *Top. Curr. Chem.*, **2013**, *341*, 69-131.
- [5] T. J. Wenzel, *Discrimination of Chiral Compounds Using NMR Spectroscopy*, John Wiley & Sons, **2007**.
- [6] T. J. Wenzel and C. D. Chisholm, *Chirality*, **2011**, *23*, 190-214.
- [7] (a) K. Tanaka and N. Fukuda, *Tetrahedron: Asymmetry*, **2009**, *20*, 111-114.
(b) C. Pena, J. Gonzalez-Sabin, I. Alfonso, F. Rebolledo and V. Gotor, *Tetrahedron*, **2008**, *64*, 7709-7717.
(c) S. Bozkurt, M. Durmaz, H.N. Naziroglu, M. Yilmaz and A. Sirit, *Tetrahedron: Asymmetry* **2011**, *22*, 541-549;
(d) W. Wang, F. Ma, X. Shen and C. Zhang, *Tetrahedron: Asymmetry*, **2007**, *18*, 832-837;
(e) Wang, W.; Shen, X.; Ma, F.; Li, Z.; Zhang, C. *Tetrahedron: Asymmetry*, **2008**, *19*, 1193-1199;
(f) Luo, Z.; Zhong, C.; Wu, X.; Fu, E., *Tetrahedron Letters*, **2008**, *49*, 3385-3390.
- [8] (a) V. Kumar, C. Pei, C. E. Olsen, S. J. C. Schaeffer, V. S. Parmar and S. V. Malhotra, *Tetrahedron: Asymmetry* **2008**, *19*, 664-671;
(b) V. Kumar, C. E. Olsen, S. J. C. Schaeffer, V. S. Parmar and S. V. Malhotra, *Org. Lett.*, **2007**, *9*, 3905-3908.
- [9] (a) W. J. Gottstein and L. C. Cheney, *J. Org. Chem.*, **1965**, *30*, 2072-2073;
(b) C. Bolchi, L. Fumagalli, B. Moroni, M. Pallavicini and E. Valoti, *Tetrahedron: Asymmetry*, **2003**, *14*, 3779-3785.
- [10] (a) M. B. Foreiter, H. Q. N. Gunaratne, P. Nockemann, K. R. Seddon, P. J. Stevenson and D. F. Wassell, *New J. Chem.*, **2013**, *37*, 515-533;
(b) T. Laaksonen, S. Heikkinen and K. Wähälä, *Org. Biol. Chem.*, **2015**, *13*, 10548-10555;
(c) T. Laaksonen, S. Heikkinen and K. Wähälä, *Molecules*, **2015**, *20*, 20873-20886.
- [11] M.B. Foreiter, H.Q.N. Gunaratne, P. Nockemann, K.R. Seddon and G. Srinivasan, *Phys. Chem. Chem. Phys.*, **2014**, *16*, 1208-1226.
- [12] (a) B. Altava, D.S. Barbosa, M. Isabel Burguete, J. Escorihuela and S.V. Luis, *Tetrahedron: Asymmetry* **2009**, *20*, 999-1003;
(b) V. Jurcik and R. Wilhelm, *Tetrahedron: Asymmetry*, **2006**, *17*, 801-810;
(c) V. Jurcik, M. Gilani and R. Wilhelm, *Eur. J. Org. Chem.* **2006**, 5103-5109;
(d) S. L. De Rooy, M. Li, D. K. Bwambok, B. El-Zahab, S. Challa and I. M. Warner, *Chirality*, **2011**, *23*, 54-62;
(e) M. Bonanni, G. Soldaini, C. Faggi, A. Goti and F. Cardona, *Synlett*, **2009**, *5*, 747-750;
(f) D. Drahonovsky, G. C. Labat, J. Sevcik and A. von Zelewsky, *Heterocycles*, **2005**, *65*, 2169-2179;
(g) M. Vasiloiu, I. Cervenka, P. Gaertner, M. Weil, K. Schröder-Bica *Tetrahedron: Asymmetry*, **2015**, *26*, 1069-1082.
- [13] (a) S. Tabassum, M. A. Gilani and R. Wilhelm, *Tetrahedron: Asymmetry*, **2011**, *22*, 1632-1639;
(b) L. Gonzalez, B. Altava, M. Bolte, M. I. Burguete and E. Garcia-Verdugo, S. V. Luis, *Eur. J. Org. Chem.*, **2012**, *26*, 4996-5009.
- [14] (a) T. Heckel, A. Winkel and R. Wilhelm, *Tetrahedron: Asymmetry* **2013**, *24*, 1127-1133;
(b) S. A. Ashraf, Y. Pornputtkul, L. A. P. Kane-Maguire and G. G. Wallace, *Aust. J. Chem.*, **2007**, *60*, 64-67;
(c) S. Luo, D. Xu, H. Yue, L. Wang, W. Yang and Z. Xu, *Tetrahedron: Asymmetry*, **2006**, *17*, 2028-2033.
- [15] L. C. Cheney, *Purification of dehydroabietylamine.*, U.S. patent 2787637, **1957**.
- [16] G. Su, L. Huo, W. Huang, H. Wang and Y. Pan, *Chin. J. Struct. Chem.*, **2009**, *28*, 693-698.
- [17] S. Stella and A. Chadha, *Tetrahedron: Asymmetry*, **2010**, *21*, 457-460.
- [18] (a) B. Job, *Ann. Chim.* **1928**, *9*, 113-203.
(b) P. MacCarthy, *Anal. Chem.* **1978**, *50*, 2165.
(c) V.M.S. Gil and N.C. Oliveira, *J. Chem. Educ.* **1990**, *67*, 473-478.
- [19] M. Perez-Trujillo, L. Castanar, E. Monteagudo, L. T. Kuhn, P. Nolis, A. Virgili, R. T. Williamson and T. Parella, *Chem. Commun.* **2014**, *50*, 10214-10217.
- [20] J. A. Aguilar, S. Faulkner, M. Nilsson and G. A. Morris, *Angew. Chem. Int. Ed. Engl.* **2010**, *49*, 3901-3903.
- [21] S. R. Chaudhari and N. Suryaprakash, *Chem. Phys. Lett.* **2013**, *555*, 286-290.
- [22] Lokesh, S. R. Chaudhari and N. Suryaprakash, *Org. Biomol. Chem.* **2014**, *12*, 993-997.
- [23] W. A. Anderson, R. Freeman, *J. Chem. Phys.* **1962**, *37*, 85 – 103.
- [24] J. P. Jesson, P. Meakin, G. Kneissel, *J. Am. Chem. Soc.* **1973**, *95*, 618 – 620. □